John Sauk, DDS, MS

John Sauk, DDS, MS

John J. Sauk, D.D.S., M.S.

Professor

Department of Surgical and Hospital Dentistry

Office of the Dean, 501 S. Preston St. - Room 240-502-852-1304 – 502-852-1281

 

Background

 

Education

  • B.S. Biochemistry, University of Detroit
  • M.S. Biochemistry, University of Detroit
  • D.D.S., University of Detroit
  • M.S. Pathology, University of Minnesota

Board Certification

  • American Board of Oral & Maxillofacial Pathology

Professional Licences

  • Michigan
  • Minnesota
  • Maryland
  • Kentucky

Research Interests

  • Cancer biomarkers
  • Personalized cancer targeting

Teaching Activities

Systemic and Oral and maxillofacial Pathology

Professional Memberships

  • American Dental Association
  • American Academy of Oral Pathology (Fellow)
  • International /American Association for Dental Research
  • American Society of Human Genetics
  • American Association for the Advancement of Science (Fellow)
  • International Association of Oral Pathologists
  • American Association of Dental Schools
  • American Society for Bone and Mineral Research
  • IADR/AADR  Expl. Path Section President (1996-1997)
  • American Head and Neck Society (1999-date) (Fellow )
  • Friends of NIDCR (2000-date)

Honors

 

  • Omicron Kappa Upsilon
  • Fellow, American Association for the Advancement of Science
  • Earl Robinson Award
  • Fellow, American College Dentists
  • Distinguished Scientist Award, Experimental Pathology, IADR
  • Fellow, American Head & Neck Society
  • Fellow, Kentucky Institute of Medicine
  • Business First, Research Partner
  • Fellow, Royal College of Physicians and Surgeons Glasgow (Honorary)

Publications (Journals-188)

 

Sauk JJOgbureke KUE, Nikitakis NG, Warburton GW, Ord RA,Waller JL, Fisher LW. Upregulation of the SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol. 43(9):920-32, 2007

Hebert C, Norris K, Scheper MA, Ord RA, Nikitakis NG, Sauk JJ: High mobility group A2 is a target for miRNA-98 in Head and Neck Squamous Cell Carcinoma. Mol Cancer  Jan 14;6:5., 2007.

Scheper MA, Nikitakis NG, Chaisuparat R, Montaner S, Sauk JJ: Sulindac sulfide inhibits tumor growth and induces apoptosis in head and neck squamous cell carcinoma in vivo and in-vitro, Neoplasia  9(3):192-9,2007.

Moreau JL, Caccamese JF, Coletti DP, Sauk JJ, Fisher JP. Tissue Engineering Solutions for Cleft Palates: Current Therapy. Journal of Oral and Maxillofacial Surgery, 65(12):2503-11, 2007.

Moutsopoulos NM, Nares S, Nikitakis N, RangelZ, Wen J, Munson P, Sauk J, and Wahl SM: Tonsil epithelial factors may influence oropharyngeal HIV transmission, Amer. J. Path. 171(2):571-9, 2007.

Gonzalez-Cuyar LF, Tavora F, Burke AP, Gocke CD, Zimrin A, Sauk JJ, Zhao XF Monomorphic post-transplant lymphoproliferative disorder of the tongue: case report and review of literature. Diagn Pathol, 2: 49, 2007 PMID: 18093326 PMCID: PMC2231341

Betz MW,  Modi PC,  Caccamese JF, Coletti DP Sauk JJ, and Fisher JP:Cyclic Acetal Hydrogel System for Bone Marrow Stromal Cell Encapsulation and Osteodifferentiation, J Biomed. Mat. Res., 86(3):662-70,2008.

Scheper MA, Nikitakis NG, and Sauk, JJ : Survivin is a downstream target and effector of the sulindac-sensitive oncogenic Stat3 signaling in head and neck cancer. Int J Oral Maxillofac Surg.36(7):632-9, 2007.

Li D, Guang W, Abuzeid WM, Roy S, Gao GP, Sauk JJ, O'Malley BW Jr: Novel Adenoviral Gene Delivery System Targeted Against Head and Neck Cancer Laryngoscope.118(4):650-8.2008.

Betz MW, Caccamese JF, Coletti DPSauk JJ, and Fisher JP: Tissue Response and Orbital Floor Regeneration Using Cyclic Acetal Hydrogels. J Biomed.  Mat. Res. Part A.;90(3):819-29.2009.

Scheper MA, Chaisuparat R, Nikitakis NG, Sauk JJ. Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas. Oral Dis. Sep;14(6):561-8,2008.

Nikitakis NG; Scheper MA; Papanikolaou VS ; Sklavounou  A and Sauk JJ. Immunohistochemical expression of the oncogenic molecules active Stat3 and surviving in benign and malignant salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 107(6):837-43, 2009.

Patel M , Patel KJ, Caccamese JF, Coletti DP , Sauk JJ and Fisher JP. Characterization of Cyclic Acetal Hydroxyapatite Nanocomposites for Craniofacial Tissue Engineering. Jol Biomed. Mat. Res. 94(2):408-18, 2010.

Patel M, Geibel, Ketan E,  Patel KJ, Caccamese JF, Domenick, Coletti D, Sauk JJ, and Fisher JP. Cyclic Acetal Hydroxyapatite Nanocomposites for Orbital Bone Regeneration. Tissue Engineering16(1):55-65, 2010.

Betz MW, John F. Caccamese JF,  Coletti DP, Sauk JJ, and John P. Fisher JP. Challenges associated with regeneration of orbital floor bone.Tissue Engineering, Part B: Reviews. 16(5):541-50, 2010

Sauk JJ, Nikitakis NG,  and Scheper MA. Are we on the brink for non surgical treatment for ameloblastoma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 110(1):68-78, 2010.

Chapters & Books

  • Heddie O. Sedano, John J. Sauk, Jr., Robert J. Gorlin, Oral manifestations of inherited disorders, Boston : Butterworths, 1977
  • Hiatt Jl, and Sauk, JJ , Embryology and Anatomy of the Salivary Glands, in Eds: Gary Ellis, Paul Auclair, and Douglas Gnepp, W.B. Saunders, Philadelphia, 1991.
  • Sauk, JJ, Classification, Grading and Staging of Salivary Gland Tumors inTextbook and Color Atlas of Salivary Gland Pathology Eds: Eric R. Carlson and Robert A. Ord, Blackwell, 2008
  • Alawi FSauk JJ. Using molecular prognostic markers as a basis for designing novel oral cancer therapeutics.  In: Claudio PP, Vogiatzi PV, editors. Cutting Edge Therapies for Cancer in the 21st Century. Bentham Science Publishers Ltd.; 2014